Great Lakes Advisors’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$705K Sell
12,088
-3,638
-23% -$215K 0.01% 529
2026
Q2
$882K Buy
15,726
+4,253
+37% +$221K 0.01% 543
2026
Q1
$550K Buy
11,473
+4,155
+57% +$182K ﹤0.01% 579
2025
Q4
$283K Buy
7,318
+535
+8% +$20.4K ﹤0.01% 705
2025
Q3
$239K Buy
6,783
+801
+13% +$29K ﹤0.01% 740
2025
Q2
$216K Buy
+5,982
New +$198K ﹤0.01% 770

Other funds holding RPRX

Great Lakes Advisors's RPRX Position: Q3 2026 in Review

Great Lakes Advisors reduced its Royalty Pharma (RPRX) stake by 23% in Q3 2026, selling an estimated $215K and leaving 12,088 shares worth $705K. The position accounts for 0.01% of the portfolio, ranked #529.

Great Lakes Advisors first reported a position in RPRX in Q2 2025 and has held it in 6 quarters since. The position peaked at $882K in Q2 2026. 703 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Great Lakes Advisors held 12,088 shares of Royalty Pharma worth $705K as of Q3 2026.
  • Great Lakes Advisors sold 3,638 Royalty Pharma shares in Q3 2026, an estimated $215K.
  • Royalty Pharma made up 0.01% of Great Lakes Advisors's portfolio in Q3 2026, its #529 holding.
  • Great Lakes Advisors first reported a position in Royalty Pharma in Q2 2025 and has held it in 6 quarters since.
  • Great Lakes Advisors's Royalty Pharma position peaked at $882K in Q2 2026.
  • 703 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Great Lakes Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.